News & Media
Expanded Commercialization of TheraCell DBF™ Technologies
Australian Biotechnologies, Australia's leading tissue bank has launched three products containing Theracell DBF™ fiber technology. Professor William Walsh presented a paper "Demineralized Bone Matrix Fibers and Spinal Fusion" at the Annual Meeting of the Australian Orthopedic Association on October 9th 2017.
Theracell Announces Patent for Enhanced Cancellous Bone Technology
Northridge, Calif. and Centennial, Colo. — May 2, 2017 — TheraCell, a regenerative medicine company, today announced the issuance of a new patent for its enhanced cancellous demineralized bone (ECS™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,636,436 entitled Compositions of and Methods for Cancellous Bone Matrix, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry.
TheraCell and AlloSource Announce Second Patent for Bone Fiber Technology
Northridge, Calif. and Centennial, Colo. — Mar. 9, 2017 — TheraCell, a regenerative medicine company, today announced it was awarded a second patent for its demineralized bone fiber (DBF™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,572,912, titled Demineralized bone fibers having controlled geometry and shapes and methods thereof, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry.read more »
TheraCell has a partnership with a large US tissue bank who have licensed manufacturing and distribution rights to certain Theracell products. They are one of the leading tissue banks world wide and offer more than 200 types of precise bone, skin, soft-tissue and custom-machined allografts for use in an array of life-saving and life-enhancing medical procedures.
TheraCell believes strongly in the power of partnerships to progress science and product development and seeks mutually rewarding partnerships. We currently have non exclusive partnerships with companies who are evaluating the synergy between TheraCell’s DBF™ fibers and growth factors and autologous cell therapy products.
Contact us to discuss partnering your technology, or any other partnership opportunities.